Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Free Cash Flow (2016 - 2025)

Immucell (ICCC) has disclosed Free Cash Flow for 16 consecutive years, with -$1.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow fell 144.11% year-over-year to -$1.8 million, compared with a TTM value of $715351.0 through Sep 2025, up 129.69%, and an annual FY2024 reading of -$107822.0, up 98.36% over the prior year.
  • Free Cash Flow was -$1.8 million for Q3 2025 at Immucell, down from $1.4 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $1.4 million in Q2 2025 and bottomed at -$3.4 million in Q1 2023.
  • Average Free Cash Flow over 5 years is -$680714.6, with a median of -$416409.0 recorded in 2021.
  • The sharpest move saw Free Cash Flow plummeted 2289.01% in 2022, then soared 257.54% in 2025.
  • Year by year, Free Cash Flow stood at -$116701.0 in 2021, then tumbled by 2289.01% to -$2.8 million in 2022, then grew by 10.31% to -$2.5 million in 2023, then skyrocketed by 92.03% to -$199267.0 in 2024, then tumbled by 791.52% to -$1.8 million in 2025.
  • Business Quant data shows Free Cash Flow for ICCC at -$1.8 million in Q3 2025, $1.4 million in Q2 2025, and $1.2 million in Q1 2025.